New 4-Serotype Dengue Fever Vaccine
Dengue, a mosquito-borne illness known for symptoms like fever, headache, muscle pain and rash, poses a significant public health challenge worldwide, particularly in Asia.
Our 4-Serotype Dengue Fever Vaccine offers a safe and effective solution. It's suitable for individuals aged 4 to 60 years and requires only two doses, administered three months apart. This advanced vaccine surpasses its predecessor by accommodating a broader age range, necessitating fewer doses and eliminating the need for prior dengue history or blood tests.
The 4-Serotype Dengue Fever Vaccine is a valuable preventive measure, especially for those at risk of dengue. It plays a crucial role in reducing the risk of severe illness and mortality.
Vaccine Efficacy*
- Provides 80.2% protection against all four serotypes of dengue fever
- Demonstrates 90.4% reduction in hospitalization rates
- Achieves maximum immunity in 4 weeks and lasts at least 4-½ years after the administration of the 2nd dose. (Reference: Supplementary Fig. S3. Lancet Global Health 2024; 12: e257-70)
Vaccine Recommendations
- Recommended for individuals aged 4-60
- Suitable for individuals whether or not they have a prior history of dengue fever; no blood test required for eligibility
- Appropriate for individuals without underlying immune system disorders
- Requires two doses, administered three months apart
Frequently Asked Questions (FAQ) regarding our New 4-Serotype Dengue Fever Vaccine, click here.
